Opinion|Videos|September 24, 2025
Final Takeaways From the Panelists
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss their final thoughts on the evolving landscape of alopecia areata (AA) treatment, summarizing key takeaways from the discussion and reflecting on future directions for patient care and therapy advancements.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Thanks to all of you for this rich and informative discussion. Before we conclude I’d like to get final thoughts from each of you.
Advertisement
Related to this article
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
3
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5